68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy

Ceci, Francesco; Castellucci, Paolo; Graziani, Tiziano; Farolfi, Andrea; Fonti, Cristina; Lodi, Filippo; Fanti, Stefano

doi:10.1007/s00259-018-4189-7

Cited by 84 publications

(67 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, the DR of PSMA‐PET was highly variable in the included studies ranging from 44% to 90%. In 5 out 8 articles with available information on PSAdt, an increase of the DR of PSMA‐PET in patients with PSAdt ≤6 months and a decrease of DR of PSMA‐PET in patients with PSAdt > 6 months were reported . Of the remaining 3 articles, one study showed an opposite trend and the other two a reduction or a raise of the DR irrespective of the value of the PSAdt.…”

Section: Resultsmentioning

confidence: 99%

“…Reviewing titles and abstracts, 29 articles were excluded: 26 because not in the field of interest of this review and 3 as reviews, editorials or letters. The full‐text versions of the remaining articles were retrieved . No additional records were found screening the references of these studies.…”

Section: Resultsmentioning

confidence: 99%

“…After reviewing the full texts, four articles were excluded from the quantitative analysis (meta‐analysis) due to insufficient data to reassess the correlation between PSA kinetics and DR of PSMA‐PET and 8 studies including about 1,400 patients were finally selected for the meta‐analysis (Figure ).…”

Section: Resultsmentioning

confidence: 99%

“…Table summarizes the characteristic of the articles correlating PSMA‐PET findings and PSA kinetics selected for the systematic review (Table ) …”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Mestre

Treglia

Ferrari

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

Background Serum prostate‐specific antigen (PSA) may predict the risk of positive positron emission tomography/computed tomography with radiolabelled prostate‐specific membrane antigen (PSMA‐PET/CT) in patients with biochemical recurrent prostate cancer (BRPCa). However, to date, there are no clear data regarding the correlation between PSA kinetics and PSMA‐PET findings. We performed a systematic review and meta‐analysis to provide evidence‐based data in this setting. Methods A comprehensive literature search of studies published through October 2018 in PubMed/MEDLINE, EMBASE and Cochrane library databases was performed. A meta‐analysis to establish the detection rate (DR) of PSMA‐PET using different cut‐off values of PSA doubling time (PSAdt) and a pooled analysis to establish whether shorter PSAdt may predict positive PSMA‐PET results was performed in patients with BRPCa. Results Twelve articles were included in the systematic review, and eight articles (including about 1400 patients) were selected for the meta‐analysis. The pooled DR including 95% confidence intervals (95%CI) of PSMA‐PET in restaging prostate cancer (PCa) patients was 72% (95%CI:60%‐82%), increasing to 83% (95%CI:75%‐90%) when PSAdt was ≤6 months and decreasing to 60% (95%CI:37%‐80%) when PSAdt was >6 months, without a statistical significant difference. PSAdt ≤6 months may predict the positive result of PSMA‐PET (pooled odds ratio: 3.22; 95%CI:1.17‐8.88). Statistical heterogeneity among the included studies was found. Conclusions PSA kinetics, and in particular shorter PSAdt, may be predictor of PSMA‐PET positivity in patients with BRPCa. Further larger studies in this setting are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Table summarizes the characteristic of the articles correlating PSMA‐PET findings and PSA kinetics selected for the systematic review (Table ) …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Mestre

Treglia

Ferrari

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Prostate‐specific membrane antigen (PSMA)‐based diagnostics using 68 Ga‐PSMA‐11 as a radioligand for positron emission tomography (PET) imaging improved the detection of primary and recurrent prostate cancer . Since 68 Ga‐PSMA‐11 PET imaging showed a significantly improved detection rate of local recurrence in particular patients with biochemical recurrence after primary curative treatment seem to benefit from this novel imaging modality . In addition, PSMA‐based therapy has been investigated as a treatment option for patients with advanced castration‐resistant prostate cancer (CRPC).…”

Section: Introductionmentioning

confidence: 99%

Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of ¹⁷⁷Lu‐PSMA‐617 in LNCaP cells

et al. 2019

View full text Add to dashboard Cite

Background Prostate‐specific membrane antigen (PSMA)‐based imaging and therapy are increasingly used in the management of prostate cancer. However, low PSMA surface expression in certain patients is a limitation for PSMA‐based technologies. We have previously shown that high doses of dutasteride, a 5α‐reductase inhibitor generally used for the treatment of benign prostatic enlargement, increase the PSMA expression in vitro. We now further analyzed the concentration‐ and time‐dependent effects of dutasteride in LNCaP cells. Methods Androgen receptor (AR) expressing prostate cancer cells (LNCaP) were treated for 7 to 14 days with vehicle control (0.1% dimethyl sulfoxide) or different concentrations of dutasteride (0.25 , 0.5 , 1 , and 5 μM). In addition to cell proliferation, PSMA surface expression was assessed using flow cytometry (FACS) and immunocytochemistry. Total PSMA and AR expression was analyzed by capillary western immunoassay (WES). In addition, tumor cell uptake and internalization assays of 177Lu‐PSMA‐617 were performed. Results Dutasteride treatment resulted in a significant upregulation of PSMA surface expression compared to vehicle control after 7 days in all tested concentrations. After 14 days a further, concentration‐dependent increase of PSMA surface expression was detectable. Total PSMA protein expression significantly increased after treatment of cells with high concentrations of dutasteride using 5 μM for 7 or 14 days. However, when lower concentrations were used total PSMA expression was not significantly altered compared to vehicle control. Further testing revealed a dose‐dependent increase in uptake and internalization of 177Lu‐PSMA‐617 after 7 and 14 days. Though, a significantly increased uptake was only observed using a 5 μM dutasteride concentration for 7 days as well as 1 and 5 μM for 14 days. Conclusion Our investigations revealed a concentration‐ and time‐dependent effect of dutasteride on PSMA expression and uptake of 177Lu‐PSMA‐617 in LNCaP cells. A short‐term treatment of patients with high doses of dutasteride might increase the detection rate of PSMA‐based imaging and increase the effect of 177Lu‐PSMA‐617 therapy via upregulation of PSMA expression.

show abstract

Prostate‐Specific Membrane Antigen (PSMA)‐Targeted Radionuclide Probes for Imaging and Therapy of Prostate Cancer

2019

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the common cancers among men. Despite the prevalence of PCa, there are still unmet medical needs in the diagnosis and treatment of metastatic prostate cancer. Prostate‐specific membrane antigen (PSMA) is a type II zinc‐dependent metalloprotease which is highly overexpressed in metastatic PCa. In the last several years, PCa imaging probes targeting PSMA have been developed in academia as well as in industry. Among them, low molecular weight PSMA‐targeted ligands based on the Glu‐urea‐Lys scaffold have been evaluated in preclinical and clinical studies. This review provides an overview of the recent development in PSMA‐targeted imaging or therapeutic probes for metastatic PCa.

show abstract

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy

Cited by 84 publications

References 26 publications

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of ¹⁷⁷Lu‐PSMA‐617 in LNCaP cells

Prostate‐Specific Membrane Antigen (PSMA)‐Targeted Radionuclide Probes for Imaging and Therapy of Prostate Cancer

Contact Info

Product

Resources

About

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy

Cited by 84 publications

References 26 publications

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of 177Lu‐PSMA‐617 in LNCaP cells

Prostate‐Specific Membrane Antigen (PSMA)‐Targeted Radionuclide Probes for Imaging and Therapy of Prostate Cancer

Contact Info

Product

Resources

About

Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of ¹⁷⁷Lu‐PSMA‐617 in LNCaP cells